| Filed On | Filing |
|---|---|
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- Advancing a novel oral small molecule in inflammatory bowel disease (IBD), with potential first-in-human trials targeted by end of 2027 |
| 05 Oct 2026 |
Form 3: Bvf Partners L P/IL, 10% owner and 9 others
Holds 4,494,462 shares of Common Stock, $0.0001 par value per share |
| 05 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure
–Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population |
| 25 Jun 2026 |
Form 4: Lynch Thomas J. Jr., Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Duty Stuart, Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Biller Scott, Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Gallagher Neil, Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Mendelsohn Michael, Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Smith Ian F, Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Gill Simba, Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Parshall B Lynne, Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 25 Jun 2026 |
Form 4: Cole Douglas G., Director
Granted 28,000 Stock Options (Right to buy) ($114K) |
| 24 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 24, 2026, Foghorn Therapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The following proposals were submitted to the Company’s stockholders at the Annual Meeting: |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | SCHEDULE 13G/A |
| 07 May 2026 | 10-Q |
Loading...